Proprietary G+FLAS CRISPR-Cas12a technology
Time: 10:50 am
day: Day Two
Details:
- gfCas12a ribonucleoprotein exhibits greater stability and editing efficiency in human cell lines
- gfCas12a accepts split crRNAs to save costs in making synthetic crRNAs
- Ready-to-use gfCas12a RNP panels for cancer genome are under development
